Niels Riedemann InflaRx's guest appearances

Niels Riedemann InflaRx

Empowered Patient Podcast

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Dr. Niels Riedemann, Co-founder and CEO of InflaRx, discusses the pervasive problem of inflammation in a host of diseases, and how InflaRx is tackling this problem with their clinical-stage antibody therapy, IFX-1. InflaRx believes that they have found the key to addressing inflammation across a range of diseases, in the form of a molecule in the blood, complement factor C5a. Their main focus is on using IFX-1, a monoclonal antibody, to block C5a and prevent its action in patients with hidradenitis suppurativa (HS), a devastating autoimmune disorder that manifests on the skin, to reduce inflammatory lesions and potentially prove an ability of IFX-1 to work in different inflammatory conditions. #inflammation #InflaRx #complementsystem #HS #immunology #IFX1 InflaRx.com

Dr. Niels Riedemann, Co-founder and CEO of InflaRx, discusses the pervasive problem of inflammation in a host of diseases, and how InflaRx is tackling this problem with their clinical-stage antibody therapy, IFX-1. InflaRx believes that they have found the key to addressing inflammation across a range of diseases, in the form of a molecule in the blood, complement factor C5a. Their main focus is on using IFX-1, a monoclonal antibody, to block C5a and prevent its action in patients with hidradenitis suppurativa (HS), a devastating autoimmune disorder that manifests on the skin, to reduce inflammatory lesions and potentially prove an ability of IFX-1 to work in different inflammatory conditions. #inflammation #InflaRx #complementsystem #HS #immunology #IFX1 <a href="http://inflarx.com" rel="noopener nofollow" target="_blank">InflaRx.com</a>

Solving the Problem of Inflammation with Dr. Niels Riedemann InflaRx